Morgan Stanley
RLMD icon

Morgan Stanley’s Relmada Therapeutics RLMD Stock Holding History

Morgan Stanley’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
82,823
-115,640
-58% -$808K ﹤0.01% 5485
2026
Q1 		$1.38M Buy
198,463
+136,106
+218% +$644K ﹤0.01% 4974
2025
Q4 		$301K Buy
62,357
+61,318
+5,902% +$205K ﹤0.01% 5754
2025
Q3 		$2.09K Buy
1,039
+187
+22% +$179 ﹤0.01% 7297
2025
Q2 		$512 Sell
852
-1,316
-61% -$675 ﹤0.01% 7446
2025
Q1 		$585 Sell
2,168
-15,029
-87% -$4.98K ﹤0.01% 7349
2024
Q4 		$8.94K Sell
17,197
-20,680
-55% -$50.4K ﹤0.01% 6845
2024
Q3 		$123K Sell
37,877
-8,299
-18% -$26.9K ﹤0.01% 5922
2024
Q2 		$139K Sell
46,176
-74,338
-62% -$269K ﹤0.01% 5836
2024
Q1 		$560K Buy
120,514
+30,404
+34% +$147K ﹤0.01% 5263
2023
Q4 		$373K Sell
90,110
-33,227
-27% -$98.4K ﹤0.01% 5442
2023
Q3 		$370K Sell
123,337
-79,400
-39% -$236K ﹤0.01% 5305
2023
Q2 		$499K Sell
202,737
-145,137
-42% -$401K ﹤0.01% 5214
2023
Q1 		$786K Sell
347,874
-140,865
-29% -$486K ﹤0.01% 4999
2022
Q4 		$1.71M Buy
488,739
+196,129
+67% +$1.72M ﹤0.01% 4557
2022
Q3 		$10.8M Sell
292,610
-22,627
-7% -$627K ﹤0.01% 2877
2022
Q2 		$5.99M Buy
315,237
+49,172
+18% +$1.07M ﹤0.01% 3596
2022
Q1 		$7.18M Sell
266,065
-307,256
-54% -$6.35M ﹤0.01% 3284
2021
Q4 		$12.9M Buy
573,321
+123,980
+28% +$2.76M ﹤0.01% 2643
2021
Q3 		$11.8M Buy
449,341
+422,982
+1,605% +$11.3M ﹤0.01% 2700
2021
Q2 		$844K Buy
26,359
+25,205
+2,184% +$875K ﹤0.01% 5184
2021
Q1 		$41K Sell
1,154
-10,462
-90% -$366K ﹤0.01% 6438
2020
Q4 		$373K Sell
11,616
-1,828
-14% -$62.8K ﹤0.01% 5252
2020
Q3 		$506K Sell
13,444
-32,443
-71% -$1.25M ﹤0.01% 4638
2020
Q2 		$2.05M Buy
45,887
+45,111
+5,813% +$1.91M ﹤0.01% 3569
2020
Q1 		$26K Sell
776
-5,972
-89% -$241K ﹤0.01% 5716
2019
Q4 		$263K Buy
+6,748
New +$205K ﹤0.01% 5293

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's RLMD Position: Q2 2026 in Review

Morgan Stanley reduced its Relmada Therapeutics (RLMD) stake by 58% in Q2 2026, selling an estimated $808K and leaving 82,823 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #5485.

Morgan Stanley first reported a position in RLMD in Q4 2019 and has held it in 27 quarters since. The position peaked at $12.9M in Q4 2021. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Morgan Stanley held 82,823 shares of Relmada Therapeutics worth $573K as of Q2 2026.
  • Morgan Stanley sold 115,640 Relmada Therapeutics shares in Q2 2026, an estimated $808K.
  • Relmada Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5485 holding.
  • Morgan Stanley first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Relmada Therapeutics position peaked at $12.9M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.